Companies Generation Bio Co.
Generation Bio CEO salary & total pay, FY2024: $1.8M
Generation Bio (GBIO) CEO salary, fiscal 2024: Geoff McDonough was paid a salary of $655,301 and $1,808,274 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Generation Bio Co.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Geoff McDonough's complete compensation dossier
A PDF and a CSV sent to your email: Geoff McDonough's pay in every fiscal year Generation Bio Co. reported it, line by line, with Geoff McDonough's equity grants and Generation Bio Co.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $3,966,762FY2022
- $2,315,263FY2023
- $1,808,274FY2024
CEO total pay was $1,808,274 in fiscal 2024, down from $2,315,263 in fiscal 2023.
FY2024: salary $655,301 · bonus $0 · stock awards $0 · option awards $790,358
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Geoff McDonough | $655,301 | $0 | $0 | $790,358 | $360,416 | $0 | $2,199 | $1,808,274 |
| President and Chief Executive Officer | ||||||||
| Matthew Stanton | 519,167 | 0 | 0 | 250,807 | 207,667 | 0 | 15,397 | 993,038 |
| Chief Scientific Officer | ||||||||
| Antionette Paone | 475,141 | 0 | 0 | 250,807 | 190,056 | 0 | 15,958 | 931,962 |
| Chief Operating Officer | ||||||||
| Phillip Samayoa | 475,000 | 0 | 0 | 250,807 | 190,000 | 0 | 15,956 | 931,763 |
| Chief Strategy Officer | ||||||||
| Matthew Norkunas | 472,442 | 0 | 0 | 250,807 | 188,977 | 0 | 2,020 | 914,246 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Geoff McDonough | $1,808,274 | $2,315,263 | $3,966,762 | ↓ −506,989 |
| Matthew Stanton | 993,038 | 1,151,338 | 1,615,614 | ↓ −158,300 |
| Antionette Paone | 931,962 | 1,070,098 | 1,582,356 | ↓ −138,136 |
| Phillip Samayoa | 931,763 | 914,874 | 1,482,616 | ↑ +16,889 |
| Matthew Norkunas | 914,246 | 1,144,331 | 1,571,892 | ↓ −230,085 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The goals of our compensation programs are to pay for performance and ensure that the interests of our employees, including our NEOs, are aligned with the interests of our stockholders and our business goals, and that the total compensation paid to each of our NEOs is fair, reasonable, and competitive. We aim to target the 50th percentile of our peer group for each compensation element for our NEOs.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Antionette Paone | OPTION | 2024-01-02 | — | — | 160,650 | — | $250,807 |
| Matthew Norkunas | OPTION | 2024-01-02 | — | — | 160,650 | — | 250,807 |
| Geoff McDonough | OPTION | 2024-01-02 | — | — | 506,250 | — | 790,358 |
| Matthew Stanton | OPTION | 2024-01-02 | — | — | 160,650 | — | 250,807 |
| Phillip Samayoa | OPTION | 2024-01-02 | — | — | 160,650 | — | 250,807 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Antionette Paone | $0 | $0 | $250,807 | 0.0% |
| Matthew Norkunas | 0 | 0 | 250,807 | 0.0% |
| Geoff McDonough | 0 | 0 | 790,358 | 0.0% |
| Matthew Stanton | 0 | 0 | 250,807 | 0.0% |
| Phillip Samayoa | 0 | 0 | 250,807 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Antionette Paone | Option | 29,532 | 1,968 | 30.25 | — |
| Antionette Paone | Option | 45,375 | 20,625 | 6.49 | — |
| Antionette Paone | Option | 75,625 | 34,375 | 5.23 | — |
| Antionette Paone | Option | 22,286 | 28,649 | 4.71 | — |
| Antionette Paone | Option | 38,156 | 38,154 | 1.39 | — |
| Antionette Paone | Option | — | 160,650 | 1.86 | — |
| Antionette Paone | RSU | — | 14,324 | — | 15,183 |
| Antionette Paone | Option | 105,230 | — | 4.59 | — |
| Antionette Paone | Option | 53,784 | — | 5.16 | — |
| Antionette Paone | Option | 14,153 | — | 5.16 | — |
| Geoff McDonough | Option | 235,313 | 15,687 | 30.25 | — |
| Geoff McDonough | Option | 257,815 | 117,185 | 6.49 | — |
| Geoff McDonough | Option | 73,829 | 94,921 | 4.71 | — |
| Geoff McDonough | Option | 120,236 | 120,234 | 1.39 | — |
| Geoff McDonough | Option | — | 506,250 | 1.86 | — |
| Geoff McDonough | RSU | — | 47,459 | — | 50,307 |
| Geoff McDonough | Option | 199,038 | — | 5.16 | — |
| Matthew Norkunas | Option | 30,772 | 2,051 | 30.25 | — |
| Matthew Norkunas | Option | 5,719 | 381 | 30.73 | — |
| Matthew Norkunas | Option | 81,815 | 37,185 | 6.49 | — |
| Matthew Norkunas | Option | 23,429 | 30,121 | 4.71 | — |
| Matthew Norkunas | Option | 38,156 | 38,154 | 1.39 | — |
| Matthew Norkunas | Option | — | 160,650 | 1.86 | — |
| Matthew Norkunas | RSU | — | 16,732 | — | 17,736 |
| Matthew Norkunas | Option | 330,000 | — | 21.41 | — |
| Matthew Stanton | Option | 68,907 | 4,593 | 30.25 | — |
| Matthew Stanton | Option | 28,125 | 1,875 | 30.73 | — |
| Matthew Stanton | Option | 81,815 | 37,185 | 6.49 | — |
| Matthew Stanton | Option | 23,429 | 30,121 | 4.71 | — |
| Matthew Stanton | Option | 38,156 | 38,154 | 1.39 | — |
| Matthew Stanton | Option | — | 160,650 | 1.86 | — |
| Matthew Stanton | RSU | — | 15,059 | — | 15,963 |
| Matthew Stanton | Option | 16,422 | — | 0.6 | — |
| Matthew Stanton | Option | 85,577 | — | 4.59 | — |
| Matthew Stanton | Option | 49,255 | — | 5.16 | — |
| Phillip Samayoa | Option | 20,625 | 1,375 | 30.25 | — |
| Phillip Samayoa | Option | 26,250 | 3,750 | 35.66 | — |
| Phillip Samayoa | Option | 40,361 | 18,345 | 6.49 | — |
| Phillip Samayoa | Option | 61,875 | 48,125 | 5.53 | — |
| Phillip Samayoa | Option | 16,054 | 20,637 | 4.71 | — |
| Phillip Samayoa | Option | 38,156 | 38,154 | 1.39 | — |
| Phillip Samayoa | Option | — | 160,650 | 1.86 | — |
| Phillip Samayoa | RSU | — | 10,317 | — | 10,936 |
| Phillip Samayoa | Option | 6,750 | — | 4.59 | — |
| Phillip Samayoa | Option | 21,406 | — | 5.16 | — |
| Phillip Samayoa | Option | 5,500 | — | 29.38 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jason RhodesIndependent · Board Chair · Talent Committee (Chair) | $85,000 | $0 | $166,476 | — | — | $251,476 |
| Charles RowlandIndependent · Audit Committee (Chair) | 55,000 | 0 | 166,476 | — | — | 221,476 |
| Ron CooperIndependent · Nominating and Corporate Governance Committee (Chair) | 48,000 | 0 | 166,476 | — | — | 214,476 |
| Anthony Quinn, M.B. Ch.B., Ph.DIndependent · Audit Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Gustav ChristensenIndependent · Audit Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Donald Nicholson, Ph.DIndependent · Talent Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Catherine Stehman-Breen, M.DIndependent · Talent Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Jeffrey Jonas, M.DIndependent · Nominating and Corporate Governance Committee | 44,000 | 0 | 166,476 | — | — | 210,476 |
| Dannielle AppelhansIndependent · Nominating and Corporate Governance Committee | 44,000 | 0 | 166,476 | — | — | 210,476 |
| Geoff McDonough, M.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 7,500 / 4,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $466,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $466,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Generation Bio as a peer
Companies that benchmark against GBIO
1 company names GBIO as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
- Alector, Inc.ALECFY2025
- Editas Medicine, Inc.EDITFY2025
- uniQure N.V.QUREFY2025
Each company listed discloses GBIO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GBIO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Generation Bio Co. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Verve Therapeutics, Inc. | 2024 | Sekar Kathiresan | $639,231 | $1,683,000 | $4,727,372 | $378,972 | $7,442,663 |
| 2 | Graphite Bio, Inc. | 2025 | Evert Schimmelpennink | 690,000 | 0 | 5,793,809 | 538,200 | 7,036,009 |
| 3 | Cartesian Therapeutics, Inc. | 2025 | Carsten Brunn | 674,000 | 973,475 | 2,314,320 | 363,960 | 4,329,868 |
| 4 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 5 | Poseida Therapeutics, Inc. | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 6 | Sana Biotechnology, Inc. | 2025 | Steven Harr | 696,140 | 425,001 | 1,327,500 | 450,369 | 2,903,010 |
| 7 | Voyager Therapeutics, Inc. | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 8 | Cabaletta Bio, Inc. | 2025 | Steven Nichtberger | 659,550 | 0 | 1,266,978 | 446,982 | 2,401,555 |
| 9 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 10 | Precision BioSciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 11 | Tenaya Therapeutics, Inc. | 2025 | Faraz Ali | 664,173 | 141,924 | 755,507 | 319,275 | 1,881,396 |
| 12 | Caribou Biosciences, Inc. | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
| 13 | Generation Bio Co. | 2024 | Geoff McDonough | 655,301 | 0 | 790,358 | 360,416 | 1,808,274 |
| 14 | Adicet Bio, Inc. | 2025 | Chen Schor | 646,294 | 0 | 512,079 | 284,592 | 1,465,747 |
| — | 2seventy bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Omega Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Generation Bio Co. | not disclosed | not disclosed | not disclosed | Compensia |
| 2seventy bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Adicet Bio, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Cabaletta Bio, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Caribou Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Cartesian Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Compensia |
| Editas Medicine, Inc. | 91% | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Entrada Therapeutics, Inc. | not disclosed | not disclosed | No | Pay Governance |
| Graphite Bio, Inc. | 130% | Option 100 | not disclosed | Aon |
| Omega Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Poseida Therapeutics, Inc. | 100% | not disclosed | not disclosed | Aon Consulting, Inc. |
| Precision BioSciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Sana Biotechnology, Inc. | 107.5% | not disclosed | not disclosed | Aon plc (Human Capital Solutions practice) |
| Tenaya Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Verve Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
| Voyager Therapeutics, Inc. | 97.5% | not disclosed | No | Alpine Rewards, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-04 | 38,082,392 | 359,912 | 22,112 | 99.06% | Passed |
| 2024 | 2024-06-06 | 47,772,176 | 373,246 | 15,125 | 99.22% | Passed |
| 2023 | 2023-06-08 | 57,779,162 | 94,302 | 15,033 | 99.84% | Passed |
| 2021 | 2021-06-09 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-04 | 99.06%a |
| 2024 | 2024-06-06 | 99.22%b |
| 2023 | 2023-06-08 | 99.84%c |
a. Approved under the standard stated in the filing — “To approve Proposal 3, stockholders holding a majority of the votes cast on the matter must vote FOR the proposal. || If you vote to ABSTAIN on Proposal 3, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on Proposal 3. As a result, broker non-votes and voting to ABSTAIN will have no effect on the voting on Proposal 3.”.
b. Approved under the standard stated in the filing — “To approve Proposal 3, stockholders holding a majority of the votes cast on the matter must vote FOR the proposal. || If you vote to ABSTAIN on Proposal 3, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on Proposal 3. As a result, broker non-votes and voting to ABSTAIN will have no effect on the voting on Proposal 3.”.
c. Approved under the standard stated in the filing — “To approve Proposal 4, stockholders holding a majority of the votes cast on the matter must vote FOR the proposal. || If you vote to ABSTAIN on Proposal 4, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on Proposal 4. As a result, broker non-votes and voting to ABSTAIN will have no effect on the voting on Proposal 4.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 8 : 1 |
|---|---|
| CEO total compensation | $1,808,274 |
| Median employee compensation | $218,104 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dannielle Appelhans | Director | 2025-06-04 | A | 30,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-07-15 | D | 5,273 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-07-15 | D | 1,548 | 0 | 659 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-07-15 | A | 5,273 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-07-15 | — | 3,326 | — | — | 3 insiders, 3 accrual rows | ||
| Phillip Samayoa | Chief Scientific Officer | 2025-07-15 | D | 337 | 0 | 144 | Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-07-15 | A | 1,147 | — | — | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-07-15 | D | 468 | 0 | 199 | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-07-15 | A | 1,592 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-07-15 | D | 173 | 0 | 74 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-07-15 | A | 587 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-07-15 | D | 3,347 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-07-15 | D | 983 | 0 | 419 | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-07-15 | A | 3,347 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-10-15 | — | 1,192 | — | — | 5 insiders, 5 accrual rows | ||
| Kevin John Conway | Chief Financial Officer | 2025-10-15 | D | 18 | 7 | 121 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-10-15 | A | 58 | — | — | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-10-15 | D | 47 | 7 | 315 | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-10-15 | A | 159 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-10-15 | D | 99 | 7 | 664 | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-10-15 | A | 334 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-15 | D | 155 | 7 | 1,040 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-15 | A | 527 | — | — | Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-10-15 | D | 34 | 7 | 228 | Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-10-15 | A | 114 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-10-31 | — | 659 | — | — | 1 insider, 1 accrual row | ||
| Geoff McDonough | Director | 2025-10-31 | D | 293 | 6 | 1,614 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-31 | A | 659 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-01-15 | — | 789 | — | — | 3 insiders, 3 accrual rows | ||
| Kevin John Conway | Chief Financial Officer | 2026-01-15 | D | 17 | 6 | 96 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-01-15 | A | 59 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2026-01-15 | D | 99 | 6 | 558 | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2026-01-15 | A | 335 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-01-15 | D | 137 | 6 | 773 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-01-15 | A | 395 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-02-02 | — | 3,490 | — | — | 3 insiders, 3 accrual rows | ||
| Yalonda Howze | Interim CEO & President | 2026-02-02 | D | 495 | 6 | 2,792 | Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO & President | 2026-02-02 | A | 1,673 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-02 | D | 550 | 6 | 3,102 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-02 | A | 1,582 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-02 | D | 72 | 6 | 406 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-02 | A | 235 | — | — | Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 3,840 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 736 | — | — | Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 1,263 | — | — | Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 13,142 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,763 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,877 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 35,525 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 249 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 5,940 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 2,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 2,585 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,399 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 621 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,061 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,192 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 2,072 | — | — | Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 950 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 7,630 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 25,102 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 11,883 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 10,710 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 3,759 | — | — | Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 4,246 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 24,046 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 16,874 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 90,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 50,624 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 37,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 25,099 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 19,903 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 27,500 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 22,646 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 138,492 | — | — | Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 21,357 | — | — | Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 7,283 | — | — | Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 29,928 | — | — | Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 60 | — | — | Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 116,693 | — | — | Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 711,193 | — | — | Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 4,246 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 53,475 | — | — | Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 4,752 | — | — | Common | Form 4 ↗ |
| Atlas Venture Fund X, L.P. | Greater-than-10% holder | 2026-02-09 | D | 60 | — | — | Common | Form 4 ↗ |
| Atlas Venture Fund X, L.P. | Greater-than-10% holder | 2026-02-09 | D | 116,693 | — | — | Common | Form 4 ↗ |
| Atlas Venture Fund X, L.P. | Greater-than-10% holder | 2026-02-09 | D | 711,193 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 158 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dannielle Appelhans | Director | 2025-06-04 | A | 30,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2025-06-04 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-07-15 | D | 5,273 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-07-15 | D | 1,548 | 0 | 659 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-07-15 | A | 5,273 | — | — | Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-07-15 | D | 1,147 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-07-15 | D | 337 | 0 | 144 | Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-07-15 | A | 1,147 | — | — | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-07-15 | D | 1,592 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-07-15 | D | 468 | 0 | 199 | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-07-15 | A | 1,592 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-07-15 | D | 587 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-07-15 | D | 173 | 0 | 74 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-07-15 | A | 587 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-07-15 | D | 3,347 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-07-15 | D | 983 | 0 | 419 | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-07-15 | A | 3,347 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-10-15 | D | 58 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-10-15 | D | 18 | 7 | 121 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2025-10-15 | A | 58 | — | — | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-10-15 | D | 159 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-10-15 | D | 47 | 7 | 315 | Common | Form 4 ↗ |
| Antionette Paone | Chief Operating Officer | 2025-10-15 | A | 159 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-10-15 | D | 334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-10-15 | D | 99 | 7 | 664 | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2025-10-15 | A | 334 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-15 | D | 527 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-15 | D | 155 | 7 | 1,040 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-15 | A | 527 | — | — | Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-10-15 | D | 114 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-10-15 | D | 34 | 7 | 228 | Common | Form 4 ↗ |
| Phillip Samayoa | Chief Scientific Officer | 2025-10-15 | A | 114 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-31 | D | 659 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-31 | D | 293 | 6 | 1,614 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2025-10-31 | A | 659 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-01-15 | D | 59 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-01-15 | D | 17 | 6 | 96 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-01-15 | A | 59 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2026-01-15 | D | 335 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2026-01-15 | D | 99 | 6 | 558 | Common | Form 4 ↗ |
| Yalonda Howze | Chief Legal Officer | 2026-01-15 | A | 335 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-01-15 | A | 395 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-01-15 | D | 137 | 6 | 773 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-01-15 | A | 395 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO & President | 2026-02-02 | D | 1,673 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO & President | 2026-02-02 | D | 495 | 6 | 2,792 | Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO & President | 2026-02-02 | A | 1,673 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-02 | D | 1,582 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-02 | D | 550 | 6 | 3,102 | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-02 | A | 1,582 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-02 | D | 235 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-02 | D | 72 | 6 | 406 | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-02 | A | 235 | — | — | Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 3,840 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 736 | — | — | Common | Form 4 ↗ |
| Dannielle Appelhans | Director | 2026-02-09 | D | 1,263 | — | — | Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2026-02-09 | D | 13,142 | — | — | Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,763 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,877 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 35,525 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 249 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 5,940 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 2,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 2,585 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,399 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 621 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,061 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 1,192 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin John Conway | Chief Financial Officer | 2026-02-09 | D | 2,072 | — | — | Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Cooper | Director | 2026-02-09 | D | 950 | — | — | Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 7,630 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 25,102 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 11,883 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 10,710 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yalonda Howze | Interim CEO and President | 2026-02-09 | D | 3,759 | — | — | Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 4,246 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 24,046 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 16,874 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 90,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 50,624 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 37,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 25,099 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 19,903 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 27,500 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 22,646 | — | — | Common | Form 4 ↗ |
| Geoff McDonough | Director | 2026-02-09 | D | 138,492 | — | — | Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-02-09 | D | 21,357 | — | — | Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 7,283 | — | — | Common | Form 4 ↗ |
| Anthony G. Quinn | Director | 2026-02-09 | D | 29,928 | — | — | Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 60 | — | — | Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 116,693 | — | — | Common | Form 4 ↗ |
| Jason Rhodes | Director | 2026-02-09 | D | 711,193 | — | — | Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 4,246 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles Rowland | Director | 2026-02-09 | D | 53,475 | — | — | Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 1,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 5,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 3,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Stehman-Breen | Director | 2026-02-09 | D | 4,752 | — | — | Common | Form 4 ↗ |
| Atlas Venture Fund X, L.P. | Greater-than-10% holder | 2026-02-09 | D | 60 | — | — | Common | Form 4 ↗ |
| Atlas Venture Fund X, L.P. | Greater-than-10% holder | 2026-02-09 | D | 116,693 | — | — | Common | Form 4 ↗ |
| Atlas Venture Fund X, L.P. | Greater-than-10% holder | 2026-02-09 | D | 711,193 | — | — | Common | Form 4 ↗ |
Sources (200 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Geoff McDonough. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 1,808,274. View filing ↗
- Section 01, Matthew Stanton. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 993,038. View filing ↗
- Section 01, Antionette Paone. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 931,962. View filing ↗
- Section 01, Phillip Samayoa. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 931,763. View filing ↗
- Section 01, Matthew Norkunas. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 914,246. View filing ↗
- Section 03, Antionette Paone OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Norkunas OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Geoff McDonough OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Stanton OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Phillip Samayoa OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-23. Section “CEO Pay Ratio”. As printed: 8 : 1. View filing ↗
- Section 08, Jason Rhodes. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 251,476. View filing ↗
- Section 08, Charles Rowland. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 221,476. View filing ↗
- Section 08, Ron Cooper. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 214,476. View filing ↗
- Section 08, Anthony Quinn, M.B. Ch.B., Ph.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Gustav Christensen. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Donald Nicholson, Ph.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Catherine Stehman-Breen, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Jeffrey Jonas, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 210,476. View filing ↗
- Section 08, Dannielle Appelhans. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 210,476. View filing ↗
- Section 08, Geoff McDonough, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Dannielle Appelhans 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Cooper 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip Samayoa 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip Samayoa 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip Samayoa 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antionette Paone 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antionette Paone 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antionette Paone 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antionette Paone 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antionette Paone 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antionette Paone 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip Samayoa 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip Samayoa 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip Samayoa 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-10-31. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-10-31. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2025-10-31. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atlas Venture Fund X, L.P. 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atlas Venture Fund X, L.P. 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atlas Venture Fund X, L.P. 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-05. Item 5.07 · say-on-pay result. As reported: 99.06% (votes for as printed: 38,082,392). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 99.22% (votes for as printed: 47,772,176). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-09. Item 5.07 · say-on-pay result. As reported: 99.84% (votes for as printed: 57,779,162). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 466,000 + equity 0 + all other 0 = 466,000, summed across the director compensation table rows.
- Verve Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. View filing ↗
- Graphite Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Graphite Bio, Inc.'s own proxy. As printed: 7,036,009. View filing ↗
- Cartesian Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cartesian Therapeutics, Inc.'s own proxy. As printed: 4,329,868. View filing ↗
- Entrada Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. View filing ↗
- Poseida Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. View filing ↗
- Sana Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. View filing ↗
- Voyager Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Voyager Therapeutics, Inc.'s own proxy. As printed: 2,508,370. View filing ↗
- Cabaletta Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cabaletta Bio, Inc.'s own proxy. As printed: 2,401,555. View filing ↗
- Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
- Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
- Tenaya Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Tenaya Therapeutics, Inc.'s own proxy. As printed: 1,881,396. View filing ↗
- Caribou Biosciences, Inc., Section 10b CEO total. DEFR 14A, filed 2026-05-01. CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. View filing ↗
- Generation Bio Co. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Generation Bio Co.'s own proxy. As printed: 1,808,274. View filing ↗
- Adicet Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. View filing ↗
- Section 10a, Editas Medicine, Inc. reciprocity. DEF 14A. Editas Medicine, Inc. names Generation Bio Co. in its own disclosed peer group (read from its most recent proxy). View filing ↗